Cancer Archives

News and Trends 16 Jan 2017

German Antibody for Cancer Diagnostics catches an Australian Eye

Wilex is selling Telix Pharmaceuticals its radiolabeled antibody for cancer applications, Redectane, to focus on the development of ADCs instead. The Australian Telix Pharmaceuticals has closed a license agreement with Wilex, in Germany, for the worldwide rights to Redectane, an antibody with diagnostic applications in renal cancer. The antibody, Rencarex (girentuximab), which binds to the […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2017

Merck partners with Big Data Unicorn to help Cancer Patients

Merck will use Palantir’s big data software to improve drug development and patient services, starting with cancer treatments. Merck will step up its data analytics capabilities in partnership with Palantir. The US company, co-founded by PayPal billionaire Peter Thiel, provides data integration and analysis software that Merck plans to use to improve patient care and […]

January 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 12 at 6.46.14 PM 1 e1484300509836

Startup Scout 13 Jan 2017

The Good, the Bad and the Cancer-Fighting Macrophage

We decided to stick around England this week and made a short trip from London to visit the young biotech Macrophage Pharma. The company is developing immuno-oncology technology that could turn ‘bad’ tumor-associated macrophages into ‘good’, cancer-fighting cells. City: Berkhamsted, UK (near London) Founded: 2014 Employees: 1-10 Financial data: €10.38M total raised Mission: Macrophage Pharma develops next-generation immunotherapies […]

January 13, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 11 Jan 2017

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Money doesn’t guarantee success, even if it’s heavy investment from the likes of the Bill & Melinda Gates Foundation. Ingmar Hoerr explains what it means for mRNA therapeutics. In a blow to the field of mRNA, the German billion-euro biotech CureVac has reported the Phase II failure of its lead candidate at JP Morgan. Aimed at prostate cancer, CV9104 did not […]

January 11, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 11 Jan 2017

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

Merck is diversifying its oncology portfolio with four new programs licensed from Vertex Pharmaceuticals, including multiple DNA damage and repair drugs. Merck has entered a licensing agreement with Boston-based Vertex Pharmaceuticals for the worldwide rights to four oncology programs. Merck has paid €220M ($230M) upfront for two clinical-stage DNA damage and repair candidates and two additional […]

January 11, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 09 at 12.40.51 PM e1483962109441

News and Trends 9 Jan 2017

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Immatics and Amgen have inked a deal to develop bispecific drug candidates for cancer that could reach over €1B in milestones. Immatics, an immuno-oncology biotech in Tübingen, Germany, has signed an agreement with biotech giant Amgen. Immatics will receive €28.5M ($30M) upfront and up to €475M ($500M) per program and Amgen will be responsible for clinical development, manufacturing and […]

January 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jan 2017

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France’s biggest pharma companies, is offering up to €1.7B to US-based Pieris Pharmaceuticals. The team will initially develop five programs that can be later expanded to up to eight. For […]

January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Jan 2017

New German Immuno-oncology Partnership takes on Solid Tumors

TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […]

January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 23 at 6.26.13 PM e1482514040545

News and Trends 28 Dec 2016

Discussing the Future of Personalized Medicine with Biotech Experts

Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […]

December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Dec 2016

The 8 Biggest Biotech Medical Fails of 2016 in Europe

Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […]

December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Dec 2016

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies. PsiOxus Therapeutics, based in Oxford, develops immuno-oncolytic viruses to treat solid tumors. Its technology attracted a partnership with Bristol-Myers Squibb earlier this year, which is now offering the British biotech an impressive €850M […]

December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

German Antibody for Cancer Diagnostics catches an Australian Eye

Merck partners with Big Data Unicorn to help Cancer Patients

The Good, the Bad and the Cancer-Fighting Macrophage

Phase II Failure: CureVac’s CEO explains Missed Efficacy Endpoint

Merck expands its Oncology Pipeline beyond Checkpoint Inhibitors

German Immuno-Oncology Biotech partners up with Biotech Giant Amgen

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

New German Immuno-oncology Partnership takes on Solid Tumors

Discussing the Future of Personalized Medicine with Biotech Experts

The 8 Biggest Biotech Medical Fails of 2016 in Europe

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!